Navigation Links
Rigel Announces Initiation of Clinical Trials in Two Immunology Programs
Date:1/5/2012

Any statements contained in this press release that are not statements of historical fact may be deemed to be forward-looking statements. Words such as "will," "may," "aim," "believe," "plan," "expect," "potential," and similar expressions are intended to identify these forward-looking statements. These forward-looking statements are based upon Rigel's current expectations and involve risks and uncertainties. There are a number of important factors that could cause Rigel's results to differ materially from those indicated by these forward-looking statements, including, without limitation, risks associated with Rigel's need for additional capital, the timing and success of preclinical studies and clinical trials and the potential problems that may arise in the research and development and approval process, market competition, risks associated with Rigel's corporate partnerships, including risks that if conflicts arise between Rigel's and its corporate partners,  the clinical development or commercialization of the affected product candidates or research programs could be delayed or terminated, as well as other risks detailed from time to time in Rigel's reports with the Securities and Exchange Commission, including its Quarterly Report on Form 10-Q for the quarter ended September 30, 2011. Rigel does not undertake any obligation to update forward-looking statements and expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein.

Contact: Raul Rodriguez
Phone: 650.624.1302
Email: invrel@rigel.com

Media Contact: Susan C. Rogers, Alchemy Consulting, Inc.
Phone: 650.430.3777
Email: susan@alchemyemail.com


'/>"/>
SOURCE Rigel Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Rigel to Present at Oppenheimer Annual Healthcare Conference
2. Rigel Announces Third Quarter 2011 Financial Results
3. Rigel to Present at Two Upcoming Investor Conferences
4. Rigel to Present at Wells Fargo Securities Healthcare Conference
5. Rigel to Present at Jefferies Global Healthcare Conference
6. Rigel Announces Pricing of Public Offering of Common Stock
7. Rigel Announces Proposed Public Offering of Common Stock
8. Rigel to Present at Bank of America Merrill Lynch Health Care Conference
9. Rigel Announces First Quarter Financial Results
10. Rigel Announces Fourth Quarter and Year End 2010 Financial Results
11. Rigel to Present at Three Upcoming Investor Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... , Dec. 23, 2014 Tianyin ... company that specializes in patented biopharmaceutical, modernized traditional ... ingredients (API) today announced that the Company achieved ... Good Manufacturing Practice (GMP) certificate of TPI,s Qionglai ... Administration,s (CFDA). The public notice period is a ...
(Date:12/24/2014)... RALEIGH, N.C. , Dec. 23, 2014 /PRNewswire/ ... (NASDAQ: ENDP ) (TSX: ENL), and BioDelivery ... today that they have submitted a New Drug Application ... Food and Drug Administration (FDA).  Buprenorphine HCl Buccal Film ... enough to require daily, around-the-clock, long-term opioid treatment and ...
(Date:12/22/2014)... 2014  CytoSorbents Corporation (OTCQB:CTSOD), a critical care ... technology to help fight deadly inflammation in critically-ill ... today announced the appointment of Dr. Gregory ... Senior Vice President of Clinical Development, effective January ... Russo is an accomplished pediatric cardiothoracic surgeon ...
Breaking Medicine Technology:TPI QLF Achieved Public Notice Status of GMP Certification 2TPI QLF Achieved Public Notice Status of GMP Certification 3Endo Pharmaceuticals and BioDelivery Sciences Announce NDA Submission for Buprenorphine HCl Buccal Film for the Management of Moderate to Severe Chronic Pain 2Endo Pharmaceuticals and BioDelivery Sciences Announce NDA Submission for Buprenorphine HCl Buccal Film for the Management of Moderate to Severe Chronic Pain 3Endo Pharmaceuticals and BioDelivery Sciences Announce NDA Submission for Buprenorphine HCl Buccal Film for the Management of Moderate to Severe Chronic Pain 4Endo Pharmaceuticals and BioDelivery Sciences Announce NDA Submission for Buprenorphine HCl Buccal Film for the Management of Moderate to Severe Chronic Pain 5CytoSorbents Appoints Dr. Gregory B. Di Russo as Senior Vice President of Clinical Development 2CytoSorbents Appoints Dr. Gregory B. Di Russo as Senior Vice President of Clinical Development 3CytoSorbents Appoints Dr. Gregory B. Di Russo as Senior Vice President of Clinical Development 4CytoSorbents Appoints Dr. Gregory B. Di Russo as Senior Vice President of Clinical Development 5
... U.S. Food and Drug Administration today announced that it ... rejection in kidney transplant patients. The test, called QMS ... drug that helps prevent rejection in kidney transplants. ... Everolimus, marketed under the trade name Zortress, was approved ...
... Nephros, Inc. (OTC Bulletin Board: NEPH ), ... for therapeutic applications, infection control, and water purification, today ... offering to its existing stockholders have been distributed. ... in the prospectus related to the rights offering, Nephros ...
Cached Medicine Technology:FDA Clears Test to Help Patients With Kidney Transplants 2Nephros Has Commenced Rights Offering 2Nephros Has Commenced Rights Offering 3Nephros Has Commenced Rights Offering 4Nephros Has Commenced Rights Offering 5
(Date:12/26/2014)... Parker & Sons, Inc. a ... heating, cooling and plumbing contractor services throughout Arizona ... in 2014 with regard to air-conditioning systems. Residential ... known for its incredibly hot summers. Working with ... and details of a wide variety of systems ...
(Date:12/25/2014)... 26, 2014 The click ... beauty, strength and durability. Today, the business announces ... is valid until Jan. 30, 2015. , Click ... traditional hardwood. BambooFlooringChina.com is a well-known brand in ... worldwide to find a reliable bamboo flooring supplier. ...
(Date:12/25/2014)... York, New York (PRWEB) December 25, 2014 ... the 2010 DePuy ASR hip recall ( http://www.consumerinjurylawyers.com/DePuy/ ) ... LLP reports. According to an Order issued in the ... 20th, the Court will convene an open conference on ... Building and United States Courthouse in West Palm Beach, ...
(Date:12/25/2014)... (PRWEB) December 26, 2014 Recently, Dylan ... dresses, has excitedly released its collection of discounted prom ... to Percy, a senior spokesman of the company, the ... of this promotion is to expand the UK market. ... in several different colors, lengths, and styles: A-line strapless, ...
(Date:12/25/2014)... BambooFlooringChina.com sells many bamboo products and the ... the company announces big discounts on its bamboo ... , BambooFlooringChina.com is the world’s leader in bamboo flooring. ... until Jan. 20, 2015. , The bamboo mats are ... natural thread. All the bamboo strips for the mats ...
Breaking Medicine News(10 mins):Health News:Parker & Sons Announces Record Demand For 24 Hour Emergency Services In 2014 With Regard To Air-Conditioning Systems 2Health News:Parker & Sons Announces Record Demand For 24 Hour Emergency Services In 2014 With Regard To Air-Conditioning Systems 3Health News:BambooFlooringChina.com: click strand woven bamboo flooring promotion valid until Jan. 30, 2015. 2Health News:Federal Court Overseeing DePuy ASR Hip Lawsuit Set to Convene Conference in January, Bernstein Liebhard LLP Reports 2Health News:Federal Court Overseeing DePuy ASR Hip Lawsuit Set to Convene Conference in January, Bernstein Liebhard LLP Reports 3Health News:Dylan Queen: Cheap Prom Dresses for the UK Market 2Health News:Various Styles of Bamboo Mats in Many Colors from BambooFlooringChina.com 2
... Lisa Esposito HealthDay Reporter , MONDAY, Dec. 12 (HealthDay ... than two-thirds of a pound, Madeline Mann was the world,s smallest ... took over the title of world,s tiniest infant, weighing in at ... days on a ventilator in the neonatal intensive care unit at ...
... University of Georgia and the Mayo Clinic in Arizona have ... model that mimics 90 percent of human breast and pancreatic ... The vaccine, described this week in the early ... of Sciences , reveals a promising new strategy for treating ...
... , MONDAY, Dec. 12 (HealthDay News) -- ... who,ve had a mastectomy, according to a new study. ... "The removal of a breast has implications for ... establishing the need that reconstruction should be offered," Dr. ...
... University of Alberta have created a deck of cards ... to weight, that parents can use to guide their ... health professionals. Researchers in the Faculty of Medicine ... ,conversation cards, based on their findings in a recently ...
... brain tumor chemotherapy Glioblastoma multiforme (GBM) is ... tumors that originate in the brain. For most patients, ... chemotherapy with temozolomide. However, many GBMs are resistant to ... by Sameer Agnihotri, at the University of Toronto, Toronto, ...
... Dec. 12 (HealthDay News) -- An advisory panel to the U.S. ... birth control patch carries a higher risk of blood clots for ... drug store shelves. The panel, which based its decision on ... to 5 that the benefits of Johnson & Johnson,s Ortho Evra ...
Cached Medicine News:Health News:World's Tiniest 'Preemies' Growing Up Healthy: Report 2Health News:World's Tiniest 'Preemies' Growing Up Healthy: Report 3Health News:Scientists develop vaccine that attacks breast cancer in mice 2Health News:Scientists develop vaccine that attacks breast cancer in mice 3Health News:Scientists develop vaccine that attacks breast cancer in mice 4Health News:After Mastectomy, Breast Reconstruction Is Safe for Older Women 2Health News:Researchers develop 'conversation cards' to broach subject of pediatric weight management 2Health News:Researchers develop 'conversation cards' to broach subject of pediatric weight management 3Health News:JCI online early table of contents: Dec. 12, 2011 2Health News:JCI online early table of contents: Dec. 12, 2011 3Health News:JCI online early table of contents: Dec. 12, 2011 4Health News:JCI online early table of contents: Dec. 12, 2011 5Health News:JCI online early table of contents: Dec. 12, 2011 6Health News:JCI online early table of contents: Dec. 12, 2011 7Health News:JCI online early table of contents: Dec. 12, 2011 8Health News:JCI online early table of contents: Dec. 12, 2011 9Health News:FDA Panel Cites Clot Risk From Contraceptive Patch 2
Determination of Activated Partial Thromboplastin Time (APTT) by STA Analyzers. Cephalin reagent with kaolin activator....
Determination of Prothrombin Time (PT) by STA Analyzers (ISI~1.3).Freeze-dried rabbit brain thromboplastin with heparin inhibitor....
Determination of Prothrombin Time (PT)by STA Analyzers (ISI~1.8).Freeze-dried rabbit brain thromboplastin with heparin inhibitor....
The ALB method used on the Dimension clinical chemistry system is an in vitro diagnostic test intended for the quantitative determination of albumin in serum...
Medicine Products: